一线抗结核药物肝损害的研究现状

摘要/Abstract

摘要： 一线口服抗结核药物异烟肼、利福平、吡嗪酰胺和乙胺丁醇易引起患者较明显的肝损害，联合应用这类药物，患者肝损害的问题更加突出。探讨抗结核药物的肝损害、发病机制和风险因素，研究抗结核药物肝损害的临床监测非常必要。肝损害的发生与年龄、性别、营养状况、嗜酒、慢乙酰化遗传表型、乙型肝炎病毒携带者等因素相关。抗结核药物引起的肝损害是可控的，应对抗结核药物加强监控与管理。

关键词: 抗结核药, 肝炎, 慢性, 药物性

Abstract: Hepatotoxicity is one of the side effects of rifampin, isoniazid, pyrazinamide and ethambutol hydrochloride, and it was particularly more serious in antituberculosis drugs combination. This review summarized the pathogenic mechanism and risk factors of hepatotoxicity caused by anti-tuberculosis drugs, and emphasized the importance of clinical monitor of hepatotoxicity. The occurrence of hepatotoxicity is related to the factors such as age, gender, nutrition status, alcohol, slow acetylation genotype and hepatitis B carriers. The administration and monitor of anti-tuberculosis therapy should be strengthened, so that the hepatotoxicity induced by drugs can be controlled.

Key words: Antitubercular agents, Hepatitis, chronic, drug-induced

贾忠吴晶马建军梁云刘渊王兴刚. 一线抗结核药物肝损害的研究现状[J]. 中国防痨杂志, 2013, 35(6): 468-471.

JIA Zhong，WU Jing，MA Jian-jun，LIANG Yun，LIU Yuan，WANG Xing-gang. Research of anti-tuberculosis drugs’ hepatotoxicity[J]. Chinese Journal of Antituberculosis, 2013, 35(6): 468-471.

参考文献

［1］World Health Organization. Global tuberculosis control 2010. Geneva：World Health Organization, 2011.
［2］Sharma SK. Antituberculosis drugs and hepatotoxicity. Infect Genet Evol, 2004, 4(2): 167-170.
［3］Devarbhavi H, Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol, 2010,105(11):2396-2404.
［4］Steele MA, Burk RF, Des Prez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest, 1991, 99(2): 465-471.
［5］Awodele O, Akintonwa A, Osunkalu VO. Modulatory activity of antioxidants against the toxicity of rifampicin in vivo. Rev Inst Med Trop Sao Paulo, 2010, 52(1): 43-46.
［6］Agal S, Baijal R, Pramanik S, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol, 2005, 20(11): 1745-1752.
［7］Fernández-Villar A,Sopea B,Fernández-Villar J, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis, 2004, 8(12): 1499-1505.
［8］杨慧媛, 宋育林, 许建明,等. 抗结核药物肝毒性研究现状及其存在的问题. 安徽医药, 2008, 12(4): 289-292.
［9］李双初, 何丙生, 代秀萍, 等. 2H₃R₃E₃Z₃/4H₃R₃方案引起的药物性肝损害及其对抗结核效果的影响. 中国防痨杂志, 2008, 30 (1): 11-14.
［10］李键, 王修齐, 杨桂仙,等. 药源性消化系统疾病. 北京:科学出版社, 2001: 265-267.
［11］赵凤芹. 抗结核药物诱导肝损伤的评价. 国外医学呼吸系统分册, 2003, 23 (6): 322-324.
［12］Saukkonen JJ,Cohn DL,Jasmer RM, et al. An official ATS statement: heap-totoxicity of antituberculosis therapy. Am J Respir Crit Care Med, 2006, 174（8）: 935-952.
［13］Harada Y, Kawakami K, Koyama K, et al. Case of fatal liver failure due to anti-tuberculous therapy. Kekkaku, 2007,82(9):705-709.
［14］Van Hest R,Baars H,Kik S, et al. Hepatotoxicity of rifamp in pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis, 2004, 39(4): 488-496.
［15］Centers for Disease Control and Prevention(CDC). Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States, 2001. MMWR Morb Mortal Wkly Rep, 2001, 50(34): 733-735.
［16］方毅敏, 陈志成, 潘四珍. 异烟肼利福平吡嗪酰胺对结核病患者肝功能的影响. 实用医学杂志, 1997, 13（9）: 609-610.
［17］Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J, 1996, 9(10): 2026-2030.
［18］Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology, 1990, 98 (2): 502-504.
［19］Yew WW, Leung CC. Antituberculosis drugs and hepatotoxi-city. Respirology, 2006, 11(6): 699-707.
［20］Mitchell JR, Thorgeirsson UP, Black M, et al. Increased incidence of isoniazid hepatitis in rapid acetylators, possible relation to hydrazine metabolities. Clin Pharmacol Ther, 1975, 18(1): 70-79.
［21］Huang YS, Chem HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology, 2002, 35(4): 883-889.
［22］Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol, 2003, 41 (11): 1226-1232.
［23］Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother, 2004, 38(6): 1074-1079.
［24］Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology, 2003, 37(4): 924-930.
［25］Roy B, Chowdhury A, Kundu S, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferaseM1 ‘null’ mutation. J Gastroenterol Hepatol, 2001,16(9): 1033-1037.
［26］Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during anti tuberculosis treatment. Am J Respir Crit Care Med, 2002, 166(7): 916-919.
［27］Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother, 2001, 45 (2): 382-392.
［28］Rae JM, Johnson MD, Lippman ME, et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther, 2001, 299(3): 849-857.
［29］Nolan CM, Sandblom RE, Thummel KE, et al. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest, 1994, 105(2): 408-411.
［30］Thummel KE, Lee CA, Kunze KL, et al. Oxidation of ace-taminophen to N-acetyl-p-aminobenzoquinoneimine by human CYP3A4. Biochem Pharmacol, 1993, 45(8): 1563-1569.
［31］Chamorro JG, Castagnino JP, Musella RM, et al. Sex, ethnicity and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol, 2013, 28(2):323-328.
［32］Mansukhani S, Shah I. Hepatic dysfunction in children with tuberculosis on treatment with antituberculous therapy. Ann Hepatol, 2012, 11(1):96-99.
［33］Lima Mde F,Melo HR. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cad Saude Publica, 2012, 28(4):698-708.
［34］Marzuki OA, Fauzi AR, Ayoub S, et al. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med, 2008, 49(9): 688-693.
［35］Sukhanov DS, Okovity SV, Demidik SN, et al. Relationship between the endogenous interferon IFN-gamma level and risk of hepatotoxic liver damage in tuberculosis patients. Eksp Klin Farmakol, 2012, 75(6):40-43.
［36］Dossing M, Wilcke JT, Askgaard DS, et al. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis, 1996, 77(4): 335-340.
［37］Shang P,Xia Y,Liu F,et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One, 2011,6(7):e21836.
［38］Wu S,Xia Y,Lv X, et al. Effect of scheduled monitoring of liver function during anti-tuberculosis treatment in a retrospective cohort in China. BMC Public Health, 2012, 12:454.

[1]	张静, 陈曦, 王彬, 付雷, 陆宇, 陈效友. 改良单叠氮丙啶-荧光定量PCR法的建立及其检测抗结核药物活性的价值[J]. 中国防痨杂志, 2020, 42(5): 472-480.
[2]	高天慧,舒薇,高静韬,陆宇,李琦. 254例耐药肺结核患者克拉霉素耐药情况及影响因素分析[J]. 中国防痨杂志, 2020, 42(3): 259-265.
[3]	陈浩,武楠楠,胡文辉,杨忠金. 抗结核药物作用新靶点及其研究进展[J]. 中国防痨杂志, 2020, 42(3): 286-292.
[4]	王静,张蒙,贺建清. 抗结核药物引起的艰难梭状芽胞杆菌相关性腹泻一例并文献复习[J]. 中国防痨杂志, 2020, 42(3): 293-296.
[5]	邱磊,张少言,郭晓燕,付际游,田黎明,张惠勇,鹿振辉. 化疗方案加芩部丹片治疗复治涂阳肺结核患者的临床价值[J]. 中国防痨杂志, 2020, 42(2): 108-114.
[6]	王雪迪,江锋,代倩兰,王京,王冬梅. 中西医联合与单纯西医治疗结核病所致药物性肝损伤的对比分析(2000—2019年文献复习)[J]. 中国防痨杂志, 2020, 42(2): 126-132.
[7]	李蒙, 路丽苹, 江琦, 洪建军, 高谦, 杨崇广, 郭晓芹. 上海市松江区肺结核患者治疗药品的种类及费用分析[J]. 中国防痨杂志, 2020, 42(12): 1329-1332.
[8]	唐亮, 鲍玉成, 张文龙. 抗结核药品对肠道菌群的改变及其对机体的影响[J]. 中国防痨杂志, 2020, 42(12): 1333-1338.
[9]	陈曦,刘忠泉,王彬,朱慧,付雷,李媛媛,陆宇. 14种抗结核药物在巨噬细胞内的抗结核活性评价[J]. 中国防痨杂志, 2019, 41(9): 993-998.
[10]	《中国防痨杂志》编委会. 耐药结核病化疗过程中药品不良反应处理的专家共识[J]. 中国防痨杂志, 2019, 41(6): 591-603.
[11]	邓国防,张培泽,杨敏,付亮. 二线注射剂治疗耐多药结核病的现状与思考[J]. 中国防痨杂志, 2019, 41(6): 604-608.
[12]	赵皎洁,陆宇. 抗结核药物药代动力学/药效学的研究及进展[J]. 中国防痨杂志, 2019, 41(6): 700-704.
[13]	郭存炳,李辉,郑淑兰. 参芪十一味颗粒治疗抗结核药物所致白细胞减少症的疗效[J]. 中国防痨杂志, 2018, 40(3): 274-279.
[14]	吴虹，李钧，安琴，等. 水飞蓟宾胶囊预防抗结核药物所致肝损伤的疗效分析[J]. 中国防痨杂志, 2017, 39(7): 757-760.
[15]	赵嫄，雷倩，党丽云，等. 抗结核药物血药浓度监测工作的思考和展望[J]. 中国防痨杂志, 2017, 39(11): 1228-1232.